FDA approves AZ's Fasenra for asthma

AstraZeneca plc (LSE:AZN; NYSE:AZN) said FDA approved Fasenra benralizumab as an add-on maintenance treatment in patients ages 12 and older with severe eosinophilic asthma.

The pharma plans to launch the drug within the coming weeks at a wholesale acquisition cost (WAC) per year of $38,000 in the first year and either $28,000 or $33,000 in a maintenance year depending on the number of doses...